TetraLogic Pharmaceuticals Corp
OTC:TLOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TetraLogic Pharmaceuticals Corp
Other Long-Term Assets
TetraLogic Pharmaceuticals Corp
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TetraLogic Pharmaceuticals Corp
OTC:TLOG
|
Other Long-Term Assets
$57.4k
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$10.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$6.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$12.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
35%
|
CAGR 10-Years
64%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$5.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
TetraLogic Pharmaceuticals Corp
Glance View
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
See Also
What is TetraLogic Pharmaceuticals Corp's Other Long-Term Assets?
Other Long-Term Assets
57.4k
USD
Based on the financial report for Dec 31, 2015, TetraLogic Pharmaceuticals Corp's Other Long-Term Assets amounts to 57.4k USD.
What is TetraLogic Pharmaceuticals Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
2%
Over the last year, the Other Long-Term Assets growth was -97%. The average annual Other Long-Term Assets growth rates for TetraLogic Pharmaceuticals Corp have been 2% over the past three years .
